These vaccines incorporated toll-like receptor (TLR) agonists or other immune stimulatory motifs into the peptide vaccine, which, when combined with VSV, led to enhanced DC maturation, higher CD8+ T-cell activation, and improved tumor control. Here, CD8A is linked to neoplasm.